The Memesto device, developed by Edgewater Safety Systems, targets a significant unmet need in the management of agitation in AD/ADRD patients, a condition affecting approximately 70% of the 7.2 million individuals in the U.S. The device aims to reduce reliance on pharmacological interventions, thereby potentially lowering healthcare costs and improving patient quality of life. The market for dementia care solutions is growing, driven by an aging population and increasing prevalence of dementia-related disorders. Competitive analysis indicates a limited number of direct competitors in the wearable therapeutic device space for dementia, positioning Memesto favorably. The successful completion of this trial could enhance Edgewater's market position and attract potential partnerships or acquisitions from larger healthcare entities focused on innovative dementia care solutions.